Company profile: Visterra
1.1 - Company Overview
Company description
- Provider of therapeutic and diagnostic products and R&D for infectious diseases, leveraging structure-based design informed by glycobiology and glycochemistry. Pipeline includes Sibeprenlimab (VIS649) for IgA nephropathy, VIS171 (modified IL-2) to activate Tregs, and VIS513 for dengue. Platforms: HIEROTOPE for epitope selection/design and ViSTAR Fc modifications.
Products and services
- HIEROTOPE® Platform: Proprietary research platform that identifies and selects promising epitopes and engineers antibodies to precisely engage them for therapeutic benefit using glycobiology and glycochemistry insights
- VIS513: Humanized monoclonal antibody that potently inhibits all four dengue virus types and is in a phase 2 trial conducted by Serum Institute of India Pvt. Ltd.
- ViSTAR™ Mutations: Proprietary Fc modifications introduced to enhance activity of lead candidates, modify half-life, and modulate effector function.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Visterra
Tectonic Therapeutics
HQ: United States
Website
- Description: Provider of GPCR-targeted biologic drug discovery and development via its GEODe platform, with clinical programs including TX45, a therapeutic protein in Phase 1B trials for Group 2 Pulmonary Hypertension in heart failure with preserved ejection fraction, and an Fc-relaxin fusion targeting the RXFP1 receptor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tectonic Therapeutics company profile →
Maverick Therapeutics
HQ: United States
Website
- Description: Provider of T cell immunotherapies for solid tumor cancers, developing breakthrough treatments with improved safety and efficacy via COBRA, the most advanced bispecific T cell engaging platform in its class designed to safely target solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maverick Therapeutics company profile →
Istari Oncology
HQ: United States
Website
- Description: Provider of novel immuno-oncology and immunotherapy platforms for glioblastoma, developing lerapolturev, an investigational immunotherapy based on the genetically modified Sabin type 1 polio vaccine targeting solid tumors, and running the LUMINOS studies: LUMINOS-101 (with pembrolizumab for recurrent glioblastoma), LUMINOS-102 (alone/with anti–PD-1 in metastatic melanoma), and LUMINOS-103 (basket study in solid tumors including bladder).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Istari Oncology company profile →
Selexys Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics under development for inflammatory and thrombotic diseases, targeting the underlying disease mechanism—adhesion of white blood cells to sites of inflammation mediated by P-selectin binding; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexys Pharmaceuticals company profile →
Tobira Therapeutics
HQ: United States
Website
- Description: Provider of research, discovery, acquisition, development, and commercialization of antiviral compounds for treating life-threatening and life-altering infectious diseases, including HIV/AIDS and hepatitis; develops TBR-652 and TBR-220 antagonists.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tobira Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Visterra
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Visterra
2.2 - Growth funds investing in similar companies to Visterra
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Visterra
4.2 - Public trading comparable groups for Visterra
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →